BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 25411085)

  • 1. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
    Bendell JC; Patel MR; Infante JR; Kurkjian CD; Jones SF; Pant S; Burris HA; Moreno O; Esquibel V; Levin W; Moore KN
    Cancer; 2015 Apr; 121(7):1056-63. PubMed ID: 25411085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.
    Li T; LoRusso P; Maitland ML; Ou SH; Bahceci E; Ball HA; Park JW; Yuen G; Tolcher A
    J Hematol Oncol; 2016 Mar; 9():23. PubMed ID: 26966027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors.
    Pant S; Burris HA; Moore K; Bendell JC; Kurkjian C; Jones SF; Moreno O; Kuhn JG; McMeekin S; Infante JR
    Invest New Drugs; 2014 Feb; 32(1):87-93. PubMed ID: 23525756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
    Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
    Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 dose escalation study of rigosertib by 2-, 4-, or 8-hour infusion twice-weekly in patients with advanced cancer.
    Advani SH; Achrekar SD; Doval DC; Raghunadharao D; Wilhelm FE; Acharya M
    Indian J Cancer; 2014; 51(1):40-4. PubMed ID: 24947095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.
    Mross K; Frost A; Steinbild S; Hedbom S; Rentschler J; Kaiser R; Rouyrre N; Trommeshauser D; Hoesl CE; Munzert G
    J Clin Oncol; 2008 Dec; 26(34):5511-7. PubMed ID: 18955456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors.
    Oh DY; Lee SH; Han SW; Kim MJ; Kim TM; Kim TY; Heo DS; Yuasa M; Yanagihara Y; Bang YJ
    Cancer Res Treat; 2015 Oct; 47(4):607-15. PubMed ID: 25715763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors.
    Wagner AJ; Messersmith WA; Shaik MN; Li S; Zheng X; McLachlan KR; Cesari R; Courtney R; Levin WJ; El-Khoueiry AB
    Clin Cancer Res; 2015 Mar; 21(5):1044-51. PubMed ID: 25388167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study.
    Brodin O; Eksborg S; Wallenberg M; Asker-Hagelberg C; Larsen EH; Mohlkert D; Lenneby-Helleday C; Jacobsson H; Linder S; Misra S; Björnstedt M
    Nutrients; 2015 Jun; 7(6):4978-94. PubMed ID: 26102212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
    Kim KP; Park SJ; Kim JE; Hong YS; Lee JL; Bae KS; Cha H; Kwon SK; Ro S; Cho J; Kim TW
    Invest New Drugs; 2015 Oct; 33(5):1048-57. PubMed ID: 26076682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.
    Beg MS; Brenner AJ; Sachdev J; Borad M; Kang YK; Stoudemire J; Smith S; Bader AG; Kim S; Hong DS
    Invest New Drugs; 2017 Apr; 35(2):180-188. PubMed ID: 27917453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors.
    Kim GM; Reid T; Shin SJ; Rha SY; Ahn JB; Lee SS; Chung HC
    Invest New Drugs; 2017 Dec; 35(6):773-781. PubMed ID: 28353123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
    Ten Bokkel Huinink WW; Sufliarsky J; Smit WM; Spanik S; Wagnerova M; Hirte HW; Kaye S; Johri AR; Oza AM
    J Clin Oncol; 2009 Jul; 27(19):3097-103. PubMed ID: 19451434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.
    Schöffski P; Thate B; Beutel G; Bolte O; Otto D; Hofmann M; Ganser A; Jenner A; Cheverton P; Wanders J; Oguma T; Atsumi R; Satomi M
    Ann Oncol; 2004 Apr; 15(4):671-9. PubMed ID: 15033678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
    Reid T; Oronsky B; Scicinski J; Scribner CL; Knox SJ; Ning S; Peehl DM; Korn R; Stirn M; Carter CA; Oronsky A; Taylor MJ; Fitch WL; Cabrales P; Kim MM; Burris HA; Lao CD; Abrouk NED; Fanger GR; Infante JR
    Lancet Oncol; 2015 Sep; 16(9):1133-1142. PubMed ID: 26296952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.
    Heath EI; Bible K; Martell RE; Adelman DC; Lorusso PM
    Invest New Drugs; 2008 Feb; 26(1):59-65. PubMed ID: 17938863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
    Dittrich C; Dumez H; Calvert H; Hanauske A; Faber M; Wanders J; Yule M; Ravic M; Fumoleau P
    Clin Cancer Res; 2003 Nov; 9(14):5195-204. PubMed ID: 14613999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
    Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
    Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.